The Fibrinolytic System in Experimental Prostate Tumor^[*]

Summary

Hypofibrinogenemia and disseminated intravascular coagulation are common events in patients with metastatic prostate carcinoma. This study tests the hypothesis that prostate tumor growth and metastasis is associated with sustained activation of fibrinolysis secondary to increased release of plasminogen activator. We implanted an androgen-insensitive prostate tumor into an inbred strain of rats and serially measured plasminogen, plasminogen activator, plasmin and fibrinogen. Control groups included animals without tumor and a group implanted with transitional cell bladder carcinoma, a locally infiltrating tumor not usually associated with hemostatic complications. Our results showed a significant and steady rise in plasma plasminogen activator, plasmin and fibrinogen levels in animals implanted with prostate cancer. This, however, is not specific for prostate tumor. Similar, perhaps more profound changes were noted in animals implanted with the transitional cell carcinoma.

Key words

Fibrinolysis - Prostate tumor

^* Supported in part by the American Cancer Society Grant # 417-67 HY.

• References

• 1 Tagnon HJ, Whitmore Jr WF, Shulman NR. Fibrinolysis in metastatic cancer of the prostate. Cancer 1952; 5: 9-12
• 2 Rasmussen J, Alberchtsen OK. Characterization of the fibrinolytic components of the human prostate. Scand J Clin Lab Invest 1960; 12: 261-268
• 3 Straub PW. Chronic intravascular coagulation.Clinical spectrum and diagnostic criteria with special emphasis on metabolism, distribution and localization of 131I-fibrinogen. Acta Med Scand (suppl) 1971; 526: 1-95
• 4 Mertins BF, Green LF, Bowie EJW, Elveback LR, Owen jr CR. Fibrinolytic split products (FSP) and ethanol gelation test in preoperative evaluation of patients with prostatic disease. Mayo Clinic Proc 1974; 49: 642-646
• 5 Owen Jr CA, Bowie EJW. Chronic intravascular coagulation and fibrinolysis (ICF) syndromes (DIC). Semin Thromb Hemostasis 1977; 3: 268-290
• 6 Al-Mondhiry H. Disseminated intravascular coagulation, experience at a major cancer center. Thromb Diath Haemorrh 1975; 34: 181-193
• 7 Pergament ML, Swaim WR, Blackard CE. Disseminated intravascular coagulation in the urologic patient. J Urol 1976; 116: 1-7
• 8 Goldenberg SL, Fenster HN, Perler Z, McLouglin MG. Disseminated intravascular coagulation in carcinoma of prostate: role ofestrogen therapy. Urology 1983; 22: 130-132
• 9 Drago JR, Goldman LB, Gerswhin ME. Chemotherapeutic & hormonal considerations of the Nb rat prostatic adenocarcinoma model. Models for Prostatic Cancer. In Prog, in Clin & Biol Res. Ser. Murphy GR. (ed) Vol 37 325-363 Alan K Liss; New York, NY: 1980
• 10 Drago JR, Goldman LB, Maurer RE, Eckels DD, Gershwin ME. Histology, histochemistry, and acid phosphatase of noble (Nb) rat prostate adenocarcinoma and treatment of an androgen-dependent Nb rat prostate adenocarcinoma. J Natl Cancer Inst 1980; 64: 931-937
• 11 Drago JR, Al-Mondhiry H. The effect of prostaglandin modulators on prostate tumor growth and metastasis. Anticancer Res 1984; 4: 391-394
• 12 Drago JR, Curley RM. Cytometrically monitored neoplastic progression in the Nb bladder cancermodel: selective proliferation of variant subpopulations. J Urol 1985; 134: 1024-1028
• 13 Winer BJ. Statistical principles in experimental design. 2nd Ed McGraw Hill Book Co.; New York: 1971
• 14 Latallo ZS, Teisseyre E, Lopaciuk S. Assessment of fibrinolytic system with use of chromogenic substrate. Haemostasis 1978; 7: 150-154
• 15 Stevens DJ, Sanfellipo MJ. Evaluation of three methods for plasma fibrinogen determination. Amer J Clin Pathol 1973; 59: 182-187
• 16 Zar JH. Binomial distribution. In: Biostatistical Analysis. 292 Prentice Hall; Englewood Cliffs, NJ: 1974
• 17 Peck SD, Reiquam CW. Disseminated intravascular coagulation in cancer patients: supportive evidence. Cancer 1973; 31: 1114-1119
• 18 Tagnon HJ, Whitmore jr WF, Schulman P, Kravitz SC. The significance of fibrinolysis occurring in patients with metastatic cancer of the prostate. Cancer 1953; 6: 63-67